Company intelligence / Profile preview

NAEJA-RGM Pharmaceuticals Inc.

Edmonton, Alberta, Canadanaeja-rgm.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has a promising new antibiotic project in preclinical development, focusing on novel solutions to drug-resistant bacteria. They have several compounds in various stages of development, with their most advanced being antifungal compounds targeting fungal CYP51A1 in preclinical phase[5][9].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

5 assets

SYN-1903

Unknown

4 more assets in the full pipeline.

Request access →

Partnerships

Previous partnerships with major international pharmaceutical companies through predecessor company NAEJA Pharmaceutical Inc.[6]

Beyond the preview

Go deeper on NAEJA-RGM Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAEJA-RGM Pharmaceuticals Inc..

Explore the full profile